Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics

Categories

[Search within category]

Predictive Optimization Of Pharmeceutical Efficacy

UCLA researchers in the Department of Mechanical and Aerospace Engineering have developed a machine learning platform to virtually screen combinatorial drug therapies.

Macrophage Programming for Immunotherapy

Immunotherapy is one of the most important areas in modern medicine. Using antibodies, proteins, and cells, physicians are now able to target a range of conditions with specificity. UC San Diego researchers have recently developed a new process for engineering macrophages to possess a broad range of sensing and programed actions for directed therapeutics.

Identification of Novel NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome is a molecular machine that becomes activated during acute and chronic inflammation and leads to production of biologically active IL-1β and IL-18 that initiate inflammatory responses triggered by tissue damage. The NLRP3 inflammasome has also been implicated in many chronic inflammatory and degenerative diseases from gout, osteoarthritis, atherosclerosis to Alzheimer’s disease. Currently, there are no effective ways to inhibit the NLRP3 inflammasome, thus there is a therapeutic need for this class of molecule.

Directed Editing Of Cellular RNA Via Nuclear Delivery Of CRISPR/Cas9

CRISPR-Cas9 technology has revolutionized the field of biological research through the introduction of sequence-specific genomic manipulation at the DNA level. It has also been reported that catalytically-dead Cas9 (dCas9) can successfully be localized to specific mRNAs within live cells. However, no system exists to perform Cas9-mediated sequence editing at the RNA level.

Diels-Alder Chemistry for Bioconjugation and Incorporation into Non-Natural Amino Acids

A bioconjugation method to covalently link molecular entities to polypeptides such as antibodies using a simple one-pot process.

TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

Novel Methodology To Convert Magnetic Resonance Imaging Scan Data To Be Used In Proton Beam Therapy

This invention is a novel model that uses magnetic resonance imaging (MRI) information to more accurately determine the irradiation area using proton beam therapy (PBT) for oncological treatment.

Generation of an Improved Synthetic Splice Modulator (FDGLY) That Mirrors the Structural Features of the Potential CLL In Vitro Inhibitor FD-895

 An increasing body of research has shown that alternations in RNA splicing are involved in a number of human diseases, particularly cancer. Drug regulation of splicing has become an interesting new target for therapeutic discovery. A number of drug discovery efforts aimed at developing splicing-modulating small-molecules are being tested in clinic trials for cancer.

Active Nanoplatform with High Drug Loading Capacity for the Diagnosis and Treatment of Cancer

Researchers at the University of California, Davis have developed an active nanoplatform (F/HAPIN) for cancer diagnosis and therapy.

Structurally Validated Anti-avß8 Antibodies for Targeting TGFß for Immunotherapy

This invention provides highly efficient antibodies whose epitopes and mechanism of action have been structurally defined against integrin αvβ8. These antibodies have been designed to be used as therapeutic for cancer. Other antibodies have been designed as companion diagnostic tools.

Nell-1 Regulates Neurogenesis And Nervous System Function

UCLA researchers in the Division of Plastic and Reconstructive Surgery at the Geffen School of Medicine and researchers at the School of Dentistry have identified neural EGFL Like 1 (Nell-1) protein as an essential molecule involved in neurogenic development and nervous system functional regulation.

Novel Covalent Inhibitors Of GTP And GDP-bound RAS

This invention describes a novel class of direct Ras inhibitors that bind and inhibit this oncogene in its GTP and GDP-bound states.

A New Class of mTOR Inhibitors for Targeted Treatment of Anti-cancer, Anti-aging, and Anti-autism and Regenerative Medicine

Novel hybrid inhibitors of mTOR (mammalian target of rapamycin kinase) that selectively target mTORC1 (mammalian target of rapamycin complex 1) and completely inhibit downstream phosphorylation of its substrates for cancer treatment as well as regenerative medicine, aging and autism (TSC mutations).

The Use of Voltammetry Based Assessment of Neurotransmitters and Metabolites in Vivo

UCLA researchers in the Departments of Medicine, Radiology and Bioengineering have developed novel methods for monitoring cardiac autonomic function in vascular and tissue compartments by measuring neurotransmitters and metabolites in vivo.

METHOD FOR DETECTING AND TREATING NASAL AND LUNG DYSBIOSIS PATIENTS WITH MICROORGANISMS

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

mTORC2 Specific Inhibitors

UCLA researchers have identified and characterized mTORC2-specific inhibitors useful as a novel treatment of glioblastoma.

Predicting, Diagnosing, And Treating Nausea And Vomiting Of Pregnancy And/Or Pregnancy Loss

UCLA researchers have identified genes associated with nausea and vomiting of pregnancy (NVP), which can be used to predict, diagnose and treat NVP and pregnancy loss.

Novel Nanoliposomal Nitroglycerin Formulation for Cardiovascular Therapies

    To address this major limitation, investigators at UCR have developed a nanoliposomal formulation of NTG, which achieves a 70-fold increase in the anti-inflammatory effect of NTG when compared to NTG. This increase in potency allows lower doses to be effective, which could mitigate the common issues seen with high clinical doses of NTG viz. loss of NTG sensitivity and endothelial toxicity. Fig. 1 Adhesion of U937 monocytes to NO-deficient (L-NIO-treated) ECs is significantly blocked by treating ECs with 5 ug/ml nanoliposomal nitroglycerin (NTG-NL). L-NIO is a selective eNOS inhibitor.  Remarkably, this anti-inflammatory dose of NTG in nanoliposomes is 70-fold lower than the dose of free NTG (5uM) required to achieve a similar effect

Preganancy Hormone-Containing Combination Products for the Continuous Treatment of Autoimmune Diseases

UCLA researchers in the Departments of Neurology have discovered that the combination of certain pregnancy hormones can treat autoimmune disorders like multiple sclerosis.

Modification of Chemical Modification of Nell-1 for Targeting to Musculosketal Tissues

UCLA researchers in the Departments of Plastic Surgery, Dentistry, and Bioengineering, have developed a novel targeted biologic for bone regenerative therapies.

Composition for Bone and Methods of Making and Using the Same

UCLA researchers in the Departments of Plastic Surgery, Bioengineering, and Dentistry have developed a method of controlling the osteoclast/osteoblast ratio for use in osteoporosis therapy.

Chemically Modified Nell-1 and Methods of Making and Using the Same

UCLA researchers have developed ways to chemically modify NELL-1, an osteoinductive factor, that significantly prolong the in vivo circulation time of the protein and retain its osteoblastic activity without any appreciable cytotoxicity.

Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.

Small Molecule Treatment for Androgen Inhibitor-Resistant Cancers

Researchers at the University of California, Davis have developed small molecule inhibitors of androgen receptor variants for the treatment of androgen inhibitor-resistant cancers.

  • Go to Page: